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Abstract
Background: Midkine is a heparin-binding growth factor that is over-expressed in various human cancers and
plays important roles in cell transformation, growth, survival, migration, and angiogenesis. However, little is
known about the upstream factors and signaling mechanisms that regulate midkine gene expression.
Methods: Two prostate cancer cell lines LNCaP and PC3 were studied for their expression of midkine. Induction
of midkine expression in LNCaP cells by serum, growth factors and cytokines was determined by Western blot
analysis and/or real-time quantitative reverse-transcription – polymerase chain reaction (RT-PCR). The cell
viability was determined by the trypan blue exclusion assay when the LNCaP cells were treated with tumor
necrosis factor alpha (TNFα) and/or recombinant midkine. When the LNCaP cells were treated with
recombinant midkine, activation of intracellular signalling pathways was determined by Western blot analysis.
Prostate tissue microarray slides containing 129 cases (18 normal prostate tissues, 40 early stage cancers, and 71
late stage cancers) were assessed for midkine expression by immunohistochemical staining.
Results: We identified that fetal bovine serum, some growth factors (epidermal growth factor, androgen, insulin-
like growth factor-I, and hepatocyte growth factor) and cytokines (TNFα and interleukin-1beta) induced midkine
expression in a human prostate cancer cell line LNCaP cells. TNFα also induced midkine expression in PC3 cells.
TNFα was the strongest inducer of midkine expression via nuclear factor-kappa B pathway. Midkine partially
inhibited TNFα-induced apoptosis in LNCaP cells. Knockdown of endogenous midkine expression by small
interfering RNA enhanced TNFα-induced apoptosis in LNCaP cells. Midkine activated extracellular signal-
regulated kinase 1/2 and p38 mitogen-activated protein kinase pathways in LNCaP cells. Furthermore, midkine
expression was significantly increased in late stage prostate cancer, which coincides with previously reported high
serum levels of TNFα in advanced prostate cancer.
Conclusion: These findings provide the first demonstration that midkine expression is induced by certain growth
factors and cytokines, particularly TNFα, which offers new insight into understanding how midkine expression is
increased in the late stage prostate cancer.
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Midkine (MDK, or MK) is a 13-kDa heparin-binding
growth factor originally identified by screening of retinoic
acid-responsive genes [1,2]. MDK plays important roles in
the nervous system, inflammation, and cancer [3-5]. MDK
has been shown to induce transformation of NIH3T3 cells
and to promote cell growth, survival, and migration, as
well as angiogenesis [6-10]. Therefore, it is not surprising
that MDK has been found to be over-expressed in various
human cancers, including esophageal, gastric, colon, pan-
creatic, hepatocellular, lung, breast, and urinary bladder
carcinomas, neuroblastomas, and Wilms' tumors [11,12].
Prostate cancer is the most common malignant disease
and the second most common cause of cancer-related
death in American men [13]. The patients succumb to
androgen-independent cancers that demonstrate altera-
tions in androgen receptor signaling, apoptosis, and neu-
roendocrine differentiation. Konishi and coworkers first
reported that MDK expression was positive in 86.3% of
clinical prostate cancer, while normal prostate tissues
were negative or showed only weak staining by immuno-
histochemical staining [14]. They also found that meta-
static lesions generally showed higher MDK expression
than the corresponding primary tumors. This was sup-
ported by a recent report that MDK expression was higher
in C4-2 cells (androgen-independent derivative of LNCaP
cells, with high tumorigenic and metastatic potential)
than in LNCaP cells [15]. However, the biological role of
MDK in prostate cancer has not been well addressed.
In this study, we found that fetal bovine serum (FBS) sig-
nificantly induced MDK expression in LNCaP cells. As the
results of searching for the serum factors that induced
MDK expression, we identified TNFα as the strongest
inducer of MDK expression in LNCaP cells. Further inves-
tigation revealed that MDK supported LNCaP cell sur-
vival.
Methods
Cell culture
Human prostate cancer cell line LNCaP and PC3 cells
were from the American Type Culture Collection (Manas-
sas, VA). LNCaP cells were routinely maintained in T-
medium (custom formula # 02-0056) with 5% FBS (Inv-
itrogen, Carlsbad, CA). PC3 cells were maintained in
Ham's F12K medium with 10% FBS. The cells were cul-
tured in a 37°C, 5% CO2 humidified incubator. To avoid
any interference from the insulin and triiodothyronine
(T3) in the T-medium, the culture medium was switched
to serum-free Dulbecco's Modified Eagles Medium
(DMEM, Invitrogen, Carlsbad, CA) 16 h after plating the
cells for all the experiments in this study. Each experiment
was repeated at least twice and only reproducible data
were presented in this report.
Analysis of MDK protein expression by Western blot 
analysis
500,000 LNCaP cells in one ml 5% FBS T-medium per
well were plated in 12-well plates and 16 h later changed
into serum-free DMEM with or without growth factors
and cytokines. There was no additional treatment during
the following 48 h. Control: serum-free DMEM + 1 µl
phosphate buffered saline (solvent for growth factors and
cytokines) +1 µl ethanol (solvent for DHT and R1881);
the concentrations of growth factors and cytokines were:
10 ng/ml recombinant human insulin, 10 ng/ml recom-
binant human IGF-I, 10 ng/ml recombinant human EGF,
10 ng/ml recombinant human HGF, 10 ng/ml recom-
binant human bFGF, 20 ng/ml T3, 10 nM DHT, 33.3 µM
all-trans-retinoic acid (RA) (Sigma-Aldrich, St. Louis,
MO); 10 nM R1881 (synthetic androgen, Perkin-Elmer,
Boston, MA); 10 ng/ml TNFα, 10 ng/ml IL-1β, 50 ng/ml
IL-6, and 50 ng/ml IL-17 (R&D Systems Inc., Minneapolis,
MN). 48 h after treatment, the culture medium was col-
lected and centrifuged at 20,800 × g for 5 min at 4°C.
LNCaP cells were also treated with different dosages (1 to
50 ng/ml) of TNFα for 48 h, or 20 ng/ml TNFα for differ-
ent time periods (8 to 48 h). PC3 cells were also treated
with or without 20 ng/ml TNFα in serum-free medium for
48 h. For Western blot analysis, 20 µl of each medium
supernatant was subjected to 12% SDS-polyacrylamide
gel electrophoresis and transferred to polyvinylidene dif-
luoride membrane by electroblotting. The membranes
were blocked with 5% nonfat dry milk in TBST (25 mM
Tris-HCl, 125 mM NaCl, 0.1% Tween 20) for 2 hours and
probed with rabbit anti-MDK antibodies (PeproTech,
Inc., Rocky Hill, NJ) overnight and then horseradish per-
oxidase-conjungated secondary antibodies for 1 hour. The
results were visualized by enhanced chemiluminescence
(SuperSignal West Pico Chemiluminescent Substrate,
Pierce Biotechnology, Inc., Rockford, IL) according to the
manufacturer's instructions. For densitometry, the inte-
grated density values (IDV) of the protein bands were ana-
lyzed by FluorChem IS-5500 (Alpha Innotech) and
normalized to the control group (arbitrarily assigned a
value of 1).
Analysis of MDK mRNA expression by real-time 
quantitative RT-PCR
Total RNA was extracted from LNCaP cells not treated or
treated with 20 ng/ml TNFα, using RNeasy Mini Kit (QIA-
GEN, Valencia, CA) with on-membrane DNase I digestion
to avoid genomic DNA contamination. cDNA was made
from total RNA using Superscript™ First-Strand Synthesis
System with oligo dT primers (Invitrogen, Carlsbad, CA).
Human MDK and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) primers were obtained from Applied
Biosystems (Foster City, CA). Real-time quantitative PCR
was done in triplicates with an ABI 7700 Sequence Detec-
tor and Sybr-Green reagents (Applied Biosystems) follow-Page 2 of 11
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normalized to GAPDH levels using the formula ∆Ct
(Cycle threshold) = Ct of MDK – Ct of GAPDH. Since
LNCaP cells without treatment for 8 h expressed the low-
est levels (but detectable, Ct = 18.3 ~ 19.0) of MDK, ∆∆Ct-
was calculated using the formula ∆∆Ct = ∆Ct of any group
– ∆Ct of LNCaP cells without treatment for 8 h. The data
were presented as fold change of MDK mRNA compared
to LNCaP cells without treatment for 8 h, where fold =
2∆∆Ct.
Inhibition of MDK expression by nuclear factor-κB (NF-
κB) inhibitor
LNCaP cells were plated as described previously. They
were not treated or treated for 48 h with increasing dos-
ages (from 1 to 20 ng/ml) of TNFα plus constant dosage
(18 µM) of a NF-κB inhibitor (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA). Alternatively, they were treated for
48 h with constant dosage (20 ng/ml) of TNFα plus
increasing dosages (from 2.25 to 18 µM) of NF-κB inhib-
itor. The medium supernatants were analyzed for MDK
protein expression by Western blot analysis as described
above.
Cell viability
20,000 LNCaP cells in one ml 5% FBS T-medium per well
in triplicate groups were plated in 12-well plates and 16 h
later changed into serum-free DMEM with or without 20
ng/ml TNFα. To test the effect of exogenous MDK on cell
survival, 0.1 or 1 µg/ml of recombinant human MDK
(PeproTech, Inc., Rocky Hill, NJ) were added 30 min
before adding TNFα. Two or four days after treatment, cell
viability was determined by the trypan blue exclusion
assay, in which cell survival was calculated as (the living
cell number of treated group ÷ the living cell number of
untreated control group) × 100. Based on our previous
experience [17], we chose to determine the cell survival
after four-day treatment to better evaluate the protective
effects of MDK (Figure 1A), while after two-day treatment
to show the combined killing effects of siRNA with TNFα
(Figure 1C).
Knockdown of endogenous MDK expression by small 
interfering RNA (siRNA)
20,000 LNCaP cells in one ml 5% FBS T-medium per well
were plated in 12-well plates and 16 h later transfected
with the mixtures of siRNA/Lipofectamine™ 2000 (Invit-
rogen, Carlsbad, CA), control-siRNA/Lipofectamine™
2000, or Lipofectamine™ 2000 only (mock transfection),
or no transfection as an additional control, according to
the manufacturer's protocol [17]. The siRNA was the ON-
TARGETplus SMARTpool pre-designed siRNA targeting
human MDK (catalog # L-003677-00, Dharmacon, Inc.,
Lafayette, CO). The control-siRNA was a scrambled
Stealth™ siRNA negative control (Invitrogen, Carlsbad,
CA). The final concentrations used were 100 nM of siRNA
or control-siRNA, and 5 µl/ml of Lipofectamine™ 2000.
Four h after transfection, the cells were changed into
serum-free DMEM without or with 20 ng/ml TNFα. Two
days later, the medium supernatants were analyzed for
MDK protein expression by Western blot analysis and the
cell viability was determined by the trypan blue exclusion
assay as described above. To confirm that the LNCaP cells
died through the caspase-3-mediated apoptosis as we
observed previously [17], the Caspase 3&7 Magic Red Kit
(Immunochemistry Technologies, LLC., Bloomington,
MN) was used to detect activated caspase-3. Briefly, a
fluorophore (cresyl violet) was coupled to the four amino
acid peptides (DEVD, optimal substrate of active caspase-
3 & 7) and not able to fluoresce. When active caspase-3 or
7 cleaved off DEVD, cresyl violet emitted red fluorescence.
Sixteen h after the siRNA transfection and TNFα treat-
ment, 20 µM MR-(DEVD)2 were added to the cells and
incubated for 1 h, followed by addition of 1 µg/ml
Hoechst 33342 for another 15 min. The red fluorescence
(indicating activation of caspase-3) and blue fluorescent
nuclei (stained by Hoechst 33342 to illustrate total cell
number) were captured by a fluorescent microscope.
Activation of intracellular signaling pathways by 
exogenous MDK
Three million LNCaP cells in 10 ml 5% FBS T-medium per
dish were plated in 100-mm dishes and 16 h later changed
into serum-free DMEM for another 16 h. Then, 100 ng/ml
recombinant human MDK was added to the cells for 5 to
480 min. The cells were harvested for protein isolation
and Western blot analysis as described previously [16,17].
The antibodies used were: pERK1/2 (pERK, Santa Cruz
Biotechnology, Santa Cruz, CA), ERK1/2, P-p38, p38, P-
Akt (serine 473), and Akt (Cell Signaling Technology, Bev-
erly, MA). For loading control, the membranes were
stripped and probed for GAPDH (antibodies from Chemi-
con, Temecula, CA). For densitometry, the IDVs of the
protein bands were analyzed by FluorChem IS-5500
(Alpha Innotech) and normalized to the control group
(arbitrarily assigned a value of 1).
Immunohistochemical staining
Prostate tissue microarray slides were prepared at the New
York University Medical Center and consisted of a total of
132 cases. Each case was represented by two 0.6-mm tis-
sue cores. Among them, 129 cases (18 normal prostate tis-
sues, 40 early stage cancers, and 71 late stage cancers) were
analyzed (3 cases lost both tissue cores). The early stage
cancer specimens were from radical prostatectomy speci-
mens derived from patients with clinically localized pros-
tate cancer. Half of this group of patients had previously
undergone neoadjuvant therapy for 3 months prior to
radical prostatectomy. The late stage cancer specimens
were from transurethral resection of hormone naïve orPage 3 of 11
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stage treatable by radical prostatectomy. Non-tumorous
prostate tissues were also derived from the radical prosta-
tectomy specimens. The collection of the specimens was
approved by the New York University Institution Review
Board.
The prostate tissue microarray slides were stained with 0.6
µg/ml rabbit anti-MDK antibodies using the VECTSTAIN
elite ABC Reagent and DAB Substrate Kit (Vector Labora-
tories, Burlingame, CA) according to the manufacturer's
protocol [16,18]. The stained slides were assessed inde-
pendently by two pathologists (X.K. and J.M.) and a con-
sensus of grading was reached. The evaluation criteria of
Konishi et al were adopted, i.e., samples were considered
Midkine partially inhibited TNFα-induced apoptosis in LNCaP cellsFigure 1
Midkine partially inhibited TNFα-induced apoptosis in LNCaP cells. A. LNCaP cells in triplicate groups were not treated (as 
control) or treated for 4 days with 20 ng/ml TNFα, without or with 0.1 or 1 µg/ml exogenous midkine; the living cell number 
was counted by the trypan blue exclusion assay; the cell survival was calculated as (the living cell number of treated group ÷ the 
living cell number of untreated control group); the data were presented as mean ± standard deviation; *P < 0.05 compared to 
TNFα alone. B. LNCaP cells were transfected with the mixtures of midkine specific siRNA/Lipofectamine™ 2000, control-
siRNA/Lipofectamine™ 2000, or Lipofectamine™ 2000 only (mock transfection), or no transfection as an additional control; 
the final concentrations used were 100 nM of siRNA or control-siRNA, and 5 µl/ml of Lipofectamine™ 2000; four h after 
transfection, the cells were changed into serum-free DMEM without or with 20 ng/ml TNFα; two days later, the medium 
supernatants were analyzed for midkine expression by Western blot. C. LNCaP cells in triplicate groups were treated as 
described in B; the cell survival after 2-days' treatment with 20 ng/ml TNFα was determined by the trypan blue exclusion assay 
as described in A; the data were presented as mean ± standard deviation; *P < 0.05 compared to the other three groups. D. 
LNCaP cells were treated as described in B; 16 h after treatment with 20 ng/ml TNFα, 20 µM MR-(DEVD)2 were added to the 
cells and incubated for 1 h, followed by addition of 1 µg/ml Hoechst 33342 for another 15 min; the red fluorescence [emitted 
by the cleaved MR-(DEVD)2 indicating activation of caspase-3] and blue fluorescent nuclei (stained by Hoechst 33342 to illus-
trate total cell number) were captured by a fluorescent microscope; original magnification: × 100.Page 4 of 11
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for MDK, weakly positive (+) if 20–50% of epithelial cells
were stained, and strongly positive (++) if more than 50%
of epithelial cells were stained [14].
Statistical analysis
The Student's t-test was used to analyze the MDK mRNA
expression data and the cell survival data. The difference
of Gleason scores between the early stage and late stage
cancers was analyzed by the Mann-Whitney U test. The
immunohistochemical staining data were analyzed by the
Kruskal-Wallis test. P < 0.05 was considered statistically
significant.
Results
Induction of MDK protein expression by growth factors 
and cytokines
In this study, we found that FBS induced MDK expression
in the human prostate cancer LNCaP cells (Figure 2A). To
rule out the possibility that the FBS contained MDK, we
loaded the same amount of FBS as in the 10% FBS
medium and did not detect any MDK signal (data not
shown). This suggested that it was serum factors in the FBS
that induced MDK expression in LNCaP cells. Therefore,
we tested a panel of thirteen growth factors and cytokines
including RA for their effects on MDK induction. Unlike
in the teratocarcinoma stem cells, RA did not induce MDK
expression in LNCaP cells. Insulin, recombinant human
basic fibroblast growth factor (bFGF), triiodothyronine
(T3), interleukin-6 (IL-6) and interleukin-17 (IL-17) did
not stimulate MDK expression, either (Figure 2A). Recom-
binant human insulin-like growth factor-I (IGF-I) and
hepatocyte growth factor (HGF) slightly induced MDK
expression, while epidermal growth factor (EGF), dihy-
drotestosterone (DHT), R1881 (synthetic androgen), and
interleukin-1β (IL-1β) modestly stimulated MDK expres-
sion (Figure 2A). However, TNFα induced a dramatic
increase in MDK expression and was the strongest inducer
among the agents tested (Figure 2A).
TNFα induced MDK expression through NF-κB pathway
Since TNFα was the strongest inducer of MDK expression
in LNCaP cells, we further characterized the induction of
MDK expression by TNFα. We found that as low as 1 ng/
ml of TNFα slightly induced MDK protein expression and
the induction was dose-dependent over a range up to 50
ng/ml (Figure 2B). Furthermore, MDK protein was
detected in the cell culture medium after 24 h treatment
with 20 ng/ml of TNFα, but not in the untreated control
medium at this point (Figure 2C). To determine if the
induction of MDK expression was at mRNA level, we did
real-time quantitative RT-PCR analysis of MDK mRNA
expression. We found that MDK mRNA expression was
significantly induced by TNFα after 24 h treatment and
continued to increase up to 48 h (Figure 2D). MDK mRNA
expression in the untreated cells also gradually and
slightly increased over time (Figure 2D), which was con-
sistent with the increase at protein level (Figure 2C). We
also found that TNFα induced MDK protein expression in
PC3 cells (Figure 2E) and LNCaP sublines C4-2, P151S,
R248W and R273H cells [19] (data not shown).
Since TNFα induces expression of many genes through
NF-κB pathway [20], we tested whether induction of MDK
expression by TNFα was also mediated by NF-κB pathway.
We utilized a synthetic cell-permeable peptide NF-κB
inhibitor that inhibits nuclear translocation of NF-κB
Midkine expression was induced by FBS, growth factors and cytokinesFigure 2
Midkine expression was induced by FBS, growth factors and 
cytokines. A. LNCaP cells were cultured in serum-free 
DMEM and treated for 48 h with 10% FBS and the indicated 
agents: 10 ng/ml insulin, 10 ng/ml IGF-I, 10 ng/ml EGF, 10 ng/
ml HGF, 10 ng/ml bFGF, 20 ng/ml T3, 10 nM R1881, 10 nM 
DHT, 10 ng/ml TNFα, 10 ng/ml IL-1β, 50 ng/ml IL-6, 50 ng/ml 
IL-17, and 33.3 µM RA. B. LNCaP cells were treated with dif-
ferent dosages (1 to 50 ng/ml) of TNFα for 48 h. C. LNCaP 
cells were also treated with 20 ng/ml TNFα for different time 
periods (8 to 48 h). 20 µl of each medium supernatant was 
subjected to Western blot analysis of midkine expression 
using rabbit anti-midkine antibodies, horseradish peroxidase-
conjungated secondary antibodies and enhanced chemilumi-
nescence reagents. D. Total RNA was extracted from 
LNCaP cells not treated or treated with 20 ng/ml TNFα, 
using RNeasy Mini Kit; cDNA was made from total RNA 
using Superscript™ First-Strand Synthesis System with oligo 
dT primers; real-time quantitative PCR was done in tripli-
cates with Sybr-Green reagents; results were normalized to 
GAPDH levels as described in Methods; the data (mean ± 
standard deviation of three independent experiments) were 
presented as fold change of midkine mRNA compared to the 
LNCaP cells without treatment for 8 h, where fold = 2∆∆Ct; 
solid bar, TNFα treated; open bar, control; * P < 0.05 and 
**P < 0.01, compared to the corresponding controls. E. PC3 
cells were cultured in serum-free medium and treated for 48 
h with or without 20 ng/ml TNFα. 20 µl of each medium 
supernatant was subjected to Western blot analysis of midk-
ine expression.Page 5 of 11
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tor completely abolished MDK protein expression
induced by 1 ng/ml TNFα, while MDK expression induced
by 5 ng/ml TNFα was inhibited to a level slightly below
the basal level of the control (Figure 3A and 3B). How-
ever, at higher dosages of TNFα, MDK expression was
decreased compared to TNFα-treated groups without the
NF-κB inhibitor, but its levels were above the basal level
(Figure 3A and 3B). In addition, inhibition of MDK induc-
tion by the NF-κB inhibitor was in a dose-dependent
manner (Figure 3C and 3D).
MDK partially inhibited TNFα-induced apoptosis in 
LNCaP cells
Given that MDK was known to prevent apoptosis in other
cell types [8,22], we tested whether exogenous MDK could
inhibit TNFα-induced apoptosis in LNCaP cells. We
found that about 28% of LNCaP cells were alive after
being treated with 20 ng/ml TNFα for 4 days, but the cell
survival rate was increased to 50% and 56% when 0.1 or
1 µg/ml recombinant human MDK was added (Figure
1A).
In addition, we used MDK-specific siRNA to knockdown
the expression of endogenous MDK. As shown in Figure
1B, TNFα induced endogenous MDK expression in the No
transfection, Mock transfection, and Control-siRNA trans-
fection groups, but not in the MDK-specific siRNA trans-
fection group. Consequently, TNFα-induced apoptosis in
LNCaP cells was enhanced by knocking down endog-
enous MDK expression. As shown in Figure 1C, the cell
survival rates in No transfection, Mock transfection, and
Control-siRNA transfection groups were about 50% after
being treated by 20 ng/ml TNFα for 2 days, while the cell
survival rate in MDK-specific siRNA transfection group
was about 25%. To confirm that the LNCaP cells died
through caspase-3-mediated apoptosis as we observed
previously [17], we used the Caspase 3&7 Magic Red Kit
to detect activation of caspase-3. We found that the cells
with active caspase-3 were very rare in both Control-
siRNA and MDK-specific siRNA transfected groups with-
out TNFα treatment. With TNFα treatment, the Control-
siRNA transfected group showed several cells with active
caspase-3 (red fluorescence) per microscopic field, while
the positive cell number was dramatically increased in the
TNFα induced midkine expression through NF-κB pathwayFigure 3
TNFα induced midkine expression through NF-κB pathway. A. LNCaP cells were not treated or treated for 48 h with increas-
ing dosages of TNFα, without (top blot) or with 18 µM NF-κB inhibitor (bottom blot); 20 µl of each medium supernatant was 
subjected to Western blot analysis of midkine expression. B. Densitometry of A; the untreated control group was arbitrarily 
assigned a value of 1; the integrated density values (IDVs) of the protein bands from other groups were divided by that of the 
control group (i.e., ratio of IDVs) to represent the relative MDK levels; solid line, TNFα only; dotted line, TNFα with 18 µM 
NF-κB inhibitor. Data presented were average ± standard deviations (error bars) of three independent experiments. C. 
LNCaP cells were not treated or treated for 48 h with 20 ng/ml TNFα, and without or with increasing dosages of NF-κB inhib-
itor; 20 µl of each medium supernatant was subjected to Western blot analysis of midkine expression. D. Densitometry of C 
as described in B. Data presented were average ± standard deviations (error bars) of three independent experiments.Page 6 of 11
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:6 http://www.biomedcentral.com/1755-8794/1/6MDK-specific siRNA transfected group (Figure 1D). Since
we have determined previously that caspase-7 in LNCaP
cells was not activated by TNFα [17], the detected signals
were specific for caspase-3.
MDK activated MAP kinase pathways
As shown in Figure 4A and 4B, MDK induced phosphor-
ylation of ERK1/2 starting 5 min after adding MDK, grad-
ually increasing to a peak at 2 h and sustaining at a lower
level thereafter for up to 8 h. It is worth pointing out that
the gradual decrease in unphosphorylated ERK1/2 was
not caused by unequal loading, as the same samples
loaded and probed for both GAPDH and unphosphor-
ylated p38 showed almost equal signals over the time
course (Figure 4A and 4B). Phosphorylation of p38
started after 1 h (Figure 4A and 4B). We found high basal
levels of phosphorylated Akt and a slight increase in P-Akt
and Akt after 1 h (Figure 4A and 4B).
MDK expression was increased in late stage prostate 
cancer
By immunohistochemical staining, we found that MDK
expression was confined primarily to the cytoplasm of
cancer cells and showed a diffuse staining pattern (Figure
5, Late Stage Cancer), which was consistent with the pre-
vious report [14]. As shown in Table 1, one out of the 18
normal prostate tissues showed weak staining for MDK,
while the rest were negative. Three out of the 40 early stage
prostate cancers were weakly positive, while 37 cases were
negative. Of the 71 late stage prostate cancers, 6 cases were
strongly positive, 24 cases were weakly positive, and 41
cases were negative. Analyzed by Kruskal-Wallis test, MDK
expression was significantly higher in the late stage high
grade prostate cancers than in the early stage intermediate
grade prostate cancers or normal prostate tissues (P <
0.001), while no significant difference was found between
the early stage prostate cancers and normal prostate tis-
sues (P > 0.05). It was noted that Gleason scores (indicat-
ing tumor differentiation) were significantly higher in the
late stage prostate cancers than in the early stage prostate
cancers (P < 0.001).
Discussion
MDK has been shown to play an important role in devel-
opment, cell survival, inflammation and tumorigenesis.
In spite of its restricted expression in adult kidney, MDK
expression is increased in disease conditions such as rheu-
matoid arthritis and cancer [5,12,23]. Intensive studies
have been performed on how and what MDK can do in
the various physiological and pathological processes.
However, the upstream factors and signaling mechanisms
that regulate MDK expression have not been identified.
MDK was first identified as a retinoic acid-responsive gene
in the teratocarcinoma stem cells [1]. Recently, MDK was
found to be upregulated by hypoxia but downregulated
by cortisol [24,25]. Rebamipide, a mucoprotective drug
used for the treatment of gastric ulcers, has been shown to
upregulate MDK expression in rat gastric mucosal cells
[26]. In this study, we found that fetal bovine serum stim-
ulated MDK expression in a prostate cancer cell line
LNCaP. Furthermore, we found that EGF, DHT, R1881,
and IL-1β modestly stimulated MDK expression, while
IGF-I and HGF slightly induced MDK expression. TNFα
was identified as the strongest inducer of MDK expression
in LNCaP cells, while insulin, bFGF, T3, IL-6, and IL-17
did not induce MDK expression in LNCaP cells. This, to
our best knowledge, was the first time to identify these
growth factors and cytokines as MDK inducers. It was rea-
sonable to speculate that induction of MDK expression by
Midkine activated MAP kinase pathways in LNCaP cellsFigure 4
Midkine activated MAP kinase pathways in LNCaP cells. A. 
The serum-starved LNCaP cells were treated with 100 ng/ml 
recombinant human MDK for 5 to 480 min; the cells were 
harvested for protein isolation and Western blot analysis of 
the indicated proteins; for loading control, the membranes 
were stripped and probed for GAPDH. B. Densitometry of 
A; the untreated control group was arbitrarily assigned a 
value of 1; IDVs of the protein bands from other groups 
were divided by that of the control group (i.e., ratio of IDVs) 
to represent the relative individual protein levels over the 
time course; of note, p38 and GAPDH lines overlapped. Data 
presented were average ± standard deviations (error bars) of 
three independent experiments.Page 7 of 11
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of low levels of TNFα, EGF, DHT, IL-1β, IGF-I, and HGF
existing in the serum. Surprisingly, RA did not induce
MDK expression in LNCaP cells, indicating a cell-specific
effect of RA.
We found that TNFα induced MDK expression in a dose-
dependent and time-dependent manner at protein levels.
At mRNA levels, TNFα-induction of MDK expression was
significant after 8 h, indicating that MDK may belong to
the late-response genes [27]. More importantly, induction
of MDK expression by TNFα was through NF-κB pathway,
as NF-κB inhibitor could dose-dependently inhibit TNFα-
induced MDK expression. Uehara and co-workers have
previously predicted a putative NF-κB-binding site in the
5' non-coding region of MDK gene [28]. In this study, we
provided the first direct evidence that MDK was a NF-κB-
inducible gene.
MDK has previously been shown to prevent apoptosis in
other cell types [8,22]. In this study, we found that exoge-
nously added recombinant human MDK partially inhib-
ited TNFα-induced apoptosis in LNCaP cells. Knocking
down the endogenous MDK expression by siRNA
enhanced TNFα-induced apoptosis through activation of
caspase-3 in LNCaP cells. These data suggested that MDK
supported LNCaP cell survival, although its strength was
not sufficient to prevent the eventual cell death in this in
vitro cell model. Our study showed that MDK also acti-
vated ERK1/2 pathway as early as within 5 minutes of
treatment in LNCaP cells. Activation of PI3k/Akt pathway
by MDK was less obvious in LNCaP cells, due to the con-
stitutively high basal level of activity [29]. Furthermore,
we found p38 pathway was dramatically activated by
MDK after one hour treatment, while c-jun NH2 terminal
kinase pathway was not activated (data not shown). Acti-
vation of the ERK1/2 pathway has been reported to prima-
rily results in cell survival, while the role of p38 pathway
is less clear, although recent studies indicate a role in cell
survival in certain cell types [30-32]. The ERK1/2 pathway
has been shown to induce BAD phosphorylation at Ser112
and thereby protect LNCaP cells from apoptosis [33,34].
Table 1: Midkine expression is increased in the late stage 
prostate cancers. Normal and prostate cancer tissue microarray 
slides were immunohistochemically stained for midkine, using 
rabbit anti-midkine antibodies and ABC elite kit with DAB 
substrate, and counterstained by hematoxylin. The grading was 
assigned to each tissue core by a consensus review of two 
pathologists. 
Tissue No. Gleason score P Midkine stain P
median (range) - + ++
Normal 18 17 1 0 §
Early stage cancer 40 6 (5 – 7) * 37 3 0 †
Late stage cancer 71 9 (8–10) 41 24 6 ‡
"-" indicates ≤ 20% of epithelial cells were immunopositive; 
"+" indicates 20–50% of epithelial cells were immunopositive; 
"++" indicates ≥ 50% of epithelial cells were immunopositive.
* P < 0.001, Gleason scores, early stage cancer v.s. late stage cancer.
§ P > 0.05, normal v.s. early stage cancer.
† P < 0.001, early stage cancer v.s. late stage cancer.
‡ P < 0.001, normal v.s. late stage cancer.
Immunohistochemical staining of prostate tissue microarraysFigure 5
Immunohistochemical staining of prostate tissue microarrays. The early stage cancers were from radical prostatectomy speci-
mens derived from patients with clinically localized prostate cancers; while the late stage cancers were derived from transure-
thral resection specimens of prostate cancers that had advanced beyond the stage treatable by radical prostatectomy; the 
normal prostate tissues were from the non-tumorous portions of the radical prostatectomy specimens; the prostate tissue 
microarray slides were stained with 0.6 µg/ml rabbit anti-midkine antibodies using the VECTSTAIN elite ABC Reagent and 
DAB Substrate Kit according to the manufacturer's protocol and counter-stained with hematoxylin; representative negative 
(Normal Epithelium and Early Stage Cancer) and strongly positive (Late Stage Cancer) midkine staining are shown; original 
magnification: × 400.Page 8 of 11
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tosis through activation of ERK1/2 and PI3k/Akt pathways
in neurons and cardiomyocytes [8,22,35]. It remains to be
tested if the same mechanism is true in prostate cancer
cells.
MDK has been found to be over-expressed in various
human cancers, including esophageal, gastric, colon, pan-
creatic, hepatocellular, lung, breast, and urinary bladder
carcinomas, as well as neuroblastomas and Wilms'
tumors [11,12]. MDK expression in prostate cancer tissues
was reported by one group [14]. In this study, we found
that the normal prostate tissues and early stage intermedi-
ate grade prostate cancers are negative or only weakly pos-
itive for MDK expression, while MDK expression is
significantly increased in the late stage prostate cancers
with higher Gleason scores. Konishi and co-workers have
previously reported that there appears to be a significant
positive correlation of MDK immunoreactivity and higher
Gleason scores [14]. However, it was noteworthy that
only 42% of the late stage cancers and 8% of the early
stage cancers were positive for MDK staining in the current
study, while 79% of the biopsied cancers (including 89%
of cancers with Gleason's pattern ≥ 4 and 68% of cancers
with Gleason's pattern ≤ 3) were positive in the previous
study [14]. This disparity may be due to using different
antibodies and staining protocols, or different sampling.
Nevertheless, Michalaki and co-workers reported that the
serum levels of TNFα in patients with locally advanced/
metastatic prostate cancers were about 4 to 6 times of
those in normal men, while the serum levels of TNFα in
patients with localized prostate cancers were only 1.3
times of those in normal men [36]. Therefore, it is possi-
ble that increased MDK expression the in late stage pros-
tate cancers may be induced by increased systemic and/or
local TNFα and other factors as identified in this study.
What remains not clear is that TNFα eventually kills
LNCaP cells in vitro, but the in vivo tumors continue to
grow in the presence of high TNFα. One possibility is that
the TNFα dosage used in our study is significantly higher
than the in vivo concentration of TNFα. It has been
reported that the normal physiological serum levels of
TNFα vary from 1 to 13 pg/ml [36-39]. Under pathologi-
cal conditions, serum TNFα levels can be as high as 53 pg/
ml in advanced stage of cancer [39], or even 368 pg/ml in
rheumatoid arthritis patients [37]. The local tissue TNFα
levels may be higher than the serum levels as serum TNFα
has a very short half-life [40,41]. It may also be possible
that TNFα induces not only MDK expression, but also
expression of other anti-apoptotic genes in vivo. MDK
may promote angiogenesis in vivo and therefore provide
further support for tumor growth [42]. Combination of
MDK specific siRNA and chemotherapy may be a promis-
ing strategy for the late stage prostate cancers as shown by
a recent study [43].
Conclusion
This study provides the first demonstration that midkine
expression is induced by certain growth factors and
cytokines, particularly TNFα, which offers new insight
into understanding how midkine expression is increased
in the late stage prostate cancers. Given the anti-apoptotic
role of MDK in prostate cancer cells, our findings further
support the new strategy to target MDK using specific
siRNA as shown by a recent study [43].
Abbreviations
bFGF, basic fibroblast growth factor; Ct, cycle threshold;
DMEM, Dulbecco's Modified Eagles Medium; DHT, dihy-
drotestosterone; EGF, epidermal growth factor; ERK,
extracellular signal-regulated kinase; FBS, fetal bovine
serum; GAPDH, glyceraldehyde-3-phosphate dehydroge-
nase; HGF, hepatocyte growth factor; IDV, integrated den-
sity values; IGF-I, insulin-like growth factor-I; IL-1β,
interleukin-1 beta; IL-6, interleukin-6; IL-17, interleukin-
17; IL-17RL, interleukin-17 receptor-like; MAP, mitogen-
activated protein; MDK or MK, midkine; NF-κB, nuclear
factor-kappa B; PI3K, phosphatidyl-inositol 3-kinase; RA,
retinoic acid; RT-PCR, reverse transcription-polymerase
chain reaction; siRNA, small interfering RNA; T3, triio-
dothyronine; TNF, tumor necrosis factor.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
ZY conceived and designed the study, performed the in
vitro experiments, and drafted the manuscript. YD and
RGE did immunohistochemical staining. XK and JM pro-
vided the prostate tissue microarray slides and evaluated
the stained slides. LAB contributed to the design and sta-
tistical analysis. All authors were involved in preparing the
manuscript.
Acknowledgements
We thank Dr. A Hari Reddi (University of California Davis) for helpful sug-
gestions and critical reading of the manuscript, Dr. Ralph W. de Vere White 
(University of California Davis) for insightful discussions, and Judy Li (Stat-
istician, University of California Davis) for help on statistics. This work was 
supported in part by a grant from U.S. Army Medical Research and Material 
Command, Department of Defense, W81XWH-05-1-0567 (to ZY) and the 
University of California Davis Cancer Center CCSG Biostatistics Shared 
Resource
References
1. Kadomatsu K, Tomomura M, Muramatsu T: cDNA cloning and
sequencing of a new gene intensely expressed in early differ-
entiation stages of embryonal carcinoma cells and in mid-
gestation period of mouse embryogenesis.  Biochem Biophys Res
Commun 1988, 151(3):1312-1318.Page 9 of 11
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:6 http://www.biomedcentral.com/1755-8794/1/62. Tomomura M, Kadomatsu K, Matsubara S, Muramatsu T: A retinoic
acid-responsive gene, MK, found in the teratocarcinoma sys-
tem. Heterogeneity of the transcript and the nature of the
translation product.  J Biol Chem 1990, 265(18):10765-10770.
3. Nakamura E, Kadomatsu K, Yuasa S, Muramatsu H, Mamiya T,
Nabeshima T, Fan QW, Ishiguro K, Igakura T, Matsubara S, Kaname
T, Horiba M, Saito H, Muramatsu T: Disruption of the midkine
gene (Mdk) resulted in altered expression of a calcium bind-
ing protein in the hippocampus of infant mice and their
abnormal behaviour.  Genes Cells 1998, 3(12):811-822.
4. Zou P, Muramatsu H, Sone M, Hayashi H, Nakashima T, Muramatsu
T: Mice doubly deficient in the midkine and pleiotrophin
genes exhibit deficits in the expression of beta-tectorin gene
and in auditory response.  Lab Invest 2006.
5. Maruyama K, Muramatsu H, Ishiguro N, Muramatsu T: Midkine, a
heparin-binding growth factor, is fundamentally involved in
the pathogenesis of rheumatoid arthritis.  Arthritis Rheum 2004,
50(5):1420-1429.
6. Kadomatsu K, Hagihara M, Akhter S, Fan QW, Muramatsu H, Mura-
matsu T: Midkine induces the transformation of NIH3T3 cells.
Br J Cancer 1997, 75(3):354-359.
7. Muramatsu H, Shirahama H, Yonezawa S, Maruta H, Muramatsu T:
Midkine, a retinoic acid-inducible growth/differentiation fac-
tor: immunochemical evidence for the function and distribu-
tion.  Dev Biol 1993, 159(2):392-402.
8. Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muram-
atsu T, Michikawa M: Midkine inhibits caspase-dependent apop-
tosis via the activation of mitogen-activated protein kinase
and phosphatidylinositol 3-kinase in cultured neurons.  J Neu-
rochem 1999, 73(5):2084-2092.
9. Qi M, Ikematsu S, Maeda N, Ichihara-Tanaka K, Sakuma S, Noda M,
Muramatsu T, Kadomatsu K: Haptotactic migration induced by
midkine. Involvement of protein-tyrosine phosphatase zeta.
Mitogen-activated protein kinase, and phosphatidylinositol
3-kinase.  J Biol Chem 2001, 276(19):15868-15875.
10. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R: An ang-
iogenic role for the neurokines midkine and pleiotrophin in
tumorigenesis.  Cancer Res 1997, 57(9):1814-1819.
11. Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M,
Takao S, Shimazu H, Ohi Y, Muramatsu T: A new family of
heparin-binding growth/differentiation factors: increased
midkine expression in Wilms' tumor and other human carci-
nomas.  Cancer Res 1993, 53(6):1281-1285.
12. Kadomatsu K, Muramatsu T: Midkine and pleiotrophin in neural
development and cancer.  Cancer Lett 2004, 204(2):127-143.
13. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer Statis-
tics, 2007.  CA Cancer J Clin 2007, 57(1):43-66.
14. Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H,
Hirao Y, Muramatsu T, Kadomatsu K: Immunohistochemical
analysis of midkine expression in human prostate carci-
noma.  Oncology 1999, 57(3):253-257.
15. Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, Gretz
N, Alken P, Michel MS: Identification of metastasis-associated
genes in prostate cancer by genetic profiling of human pros-
tate cancer cell lines.  Anticancer Res 2005, 25(1A):183-191.
16. You Z, DuRaine G, Tien JY, Lee C, Moseley TA, Reddi AH: Expres-
sion of interleukin-17B in mouse embryonic limb buds and
regulation by BMP-7 and bFGF.  Biochem Biophys Res Commun
2005, 326(3):624-631.
17. You Z, Shi XB, DuRaine G, Haudenschild D, Tepper CG, Lo SH, Gan-
dour-Edwards R, de Vere White RW, Reddi AH: Interleukin-17
receptor-like gene is a novel antiapoptotic gene highly
expressed in androgen-independent prostate cancer.  Cancer
Res 2006, 66(1):175-183.
18. Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH: Bone
morphogenetic protein (BMP)-6 signaling and BMP antago-
nist noggin in prostate cancer.  Cancer Res 2004,
64(22):8276-8284.
19. Nesslinger NJ, Shi XB, deVere White RW: Androgen-independent
growth of LNCaP prostate cancer cells is mediated by gain-
of-function mutant p53.  Cancer Res 2003, 63(9):2228-2233.
20. You Z, Ouyang H, Lopatin D, Polver PJ, Wang CY: Nuclear factor-
kappa B-inducible death effector domain-containing protein
suppresses tumor necrosis factor-mediated apoptosis by
inhibiting caspase-8 activity.  J Biol Chem 2001,
276(28):26398-26404.
21. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J: Inhibition of
nuclear translocation of transcription factor NF-kappa B by
a synthetic peptide containing a cell membrane-permeable
motif and nuclear localization sequence.  J Biol Chem 1995,
270(24):14255-14258.
22. Owada K, Sanjyo N, Kobayashi T, Kamata T, Mizusawa H, Muramatsu
H, Muramatsu T, Michikawa M: Midkine inhibits apoptosis via
extracellular signal regulated kinase (ERK) activation in
PC12 cells.  J Med Dent Sci 1999, 46(1):45-51.
23. Muramatsu T: Midkine and pleiotrophin: two related proteins
involved in development, survival, inflammation and tumor-
igenesis.  J Biochem (Tokyo) 2002, 132(3):359-371.
24. Kaplan F, Comber J, Sladek R, Hudson TJ, Muglia LJ, Macrae T, Gag-
non S, Asada M, Brewer JA, Sweezey NB: The growth factor mid-
kine is modulated by both glucocorticoid and retinoid in fetal
lung development.  Am J Respir Cell Mol Biol 2003, 28(1):33-41.
25. Reynolds PR, Mucenski ML, Le Cras TD, Nichols WC, Whitsett JA:
Midkine is regulated by hypoxia and causes pulmonary vas-
cular remodeling.  J Biol Chem 2004, 279(35):37124-37132.
26. Yuki T, Ishihara S, Rumi M, Ortega-Cava Cesar F, Kadowaki Y, Kazu-
mori H, Yuki M, Wada T, Miyaoka Y, Yoshino N, Kinoshita Y:
Expression of midkine and receptor-like protein tyrosine
phosphatase (RPTP)-beta genes in the rat stomach and the
influence of rebamipide.  Aliment Pharmacol Ther 2003, 18 Suppl
1:106-112.
27. Zhou J, Jin Y, Gao Y, Wang H, Hu G, Huang Y, Chen Q, Feng M, Wu
C: Genomic-scale analysis of gene expression profiles in
TNF-alpha treated human umbilical vein endothelial cells.
Inflamm Res 2002, 51(7):332-341.
28. Uehara K, Matsubara S, Kadomatsu K, Tsutsui J, Muramatsu T:
Genomic structure of human midkine (MK), a retinoic acid-
responsive growth/differentiation factor.  J Biochem (Tokyo)
1992, 111(5):563-567.
29. Lin J, Adam RM, Santiestevan E, Freeman MR: The phosphatidyli-
nositol 3'-kinase pathway is a dominant growth factor-acti-
vated cell survival pathway in LNCaP human prostate
carcinoma cells.  Cancer Res 1999, 59(12):2891-2897.
30. Luschen S, Scherer G, Ussat S, Ungefroren H, Adam-Klages S: Inhi-
bition of p38 mitogen-activated protein kinase reduces TNF-
induced activation of NF-kappaB, elicits caspase activity, and
enhances cytotoxicity.  Exp Cell Res 2004, 293(2):196-206.
31. Ricote M, Garcia-Tunon I, Bethencourt F, Fraile B, Onsurbe P, Pania-
gua R, Royuela M: The p38 transduction pathway in prostatic
neoplasia.  The Journal of pathology 2006, 208(3):401-407.
32. Maroni PD, Koul S, Meacham RB, Koul HK: Mitogen Activated
Protein kinase signal transduction pathways in the prostate.
Cell Commun Signal 2004, 2(1):5.
33. Kulik G, Carson JP, Vomastek T, Overman K, Gooch BD, Srinivasula
S, Alnemri E, Nunez G, Weber MJ: Tumor necrosis factor alpha
induces BID cleavage and bypasses antiapoptotic signals in
prostate cancer LNCaP cells.  Cancer Res 2001, 61(6):2713-2719.
34. Sastry KSR, Karpova Y, Kulik G: Epidermal Growth Factor Pro-
tects Prostate Cancer Cells from Apoptosis by Inducing
BAD Phosphorylation via Redundant Signaling Pathways.  J
Biol Chem 2006, 281(37):27367-27377.
35. Horiba M, Kadomatsu K, Yasui K, Lee JK, Takenaka H, Sumida A,
Kamiya K, Chen S, Sakuma S, Muramatsu T, Kodama I: Midkine
plays a protective role against cardiac ischemia/reperfusion
injury through a reduction of apoptotic reaction.  Circulation
2006, 114(16):1713-1720.
36. Michalaki V, Syrigos K, Charles P, Waxman J: Serum levels of IL-6
and TNF-alpha correlate with clinicopathological features
and patient survival in patients with prostate cancer.  Br J Can-
cer 2004, 90(12):2312-2316.
37. Top C, Tuncel A, Öncül O, Özkan S, Koçak N, Çavuslu S, Danaci M:
The Correlation Of Insulin Resistance With Serum TNF-α
Levels In Patients With Rheumatoid Artritis.  The Internet Jour-
nal of Rheumatology 2002, 1(1):.
38. Diez JJ, Hernanz A, Medina S, Bayon C, Iglesias P: Serum concen-
trations of tumour necrosis factor-alpha (TNF-alpha) and
soluble TNF-alpha receptor p55 in patients with hypothy-
roidism and hyperthyroidism before and after normalization
of thyroid function.  Clinical endocrinology 2002, 57(4):515-521.
39. Jablonska E, Piotrowski L, Grabowska Z: Serum Levels of IL-1b,
IL-6, TNF-a, sTNF-RI and CRP in Patients with Oral Cavity
Cancer.  Pathol Oncol Res 1997, 3(2):126-129.Page 10 of 11
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:6 http://www.biomedcentral.com/1755-8794/1/6Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
40. Briscoe H, Roach DR, Meadows N, Rathjen D, Britton WJ: A novel
tumor necrosis factor (TNF) mimetic peptide prevents
recrudescence of Mycobacterium bovis bacillus Calmette-
Guerin (BCG) infection in CD4+ T cell-depleted mice.  Journal
of Leukocyte Biology 2000, 68(4):538-544.
41. Pang XP, Yoshimura M, Hershman JM: Suppression of rat thyro-
troph and thyroid cell function by tumor necrosis factor-
alpha.  Thyroid 1993, 3(4):325-330.
42. Muramaki M, Miyake H, Hara I, Kamidono S: Introduction of mid-
kine gene into human bladder cancer cells enhances their
malignant phenotype but increases their sensitivity to
antiangiogenic therapy.  Clin Cancer Res 2003, 9(14):5152-5160.
43. Takei Y, Kadomatsu K, Goto T, Muramatsu T: Combinational anti-
tumor effect of siRNA against midkine and paclitaxel on
growth of human prostate cancer xenografts.  Cancer 2006,
107(4):864-873.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1755-8794/1/6/prepubPage 11 of 11
(page number not for citation purposes)
